Types segmentation classifies therapeutic agents according to their mechanism of action, reflecting distinct pathways addressed in encephalomyelitis management. Antiviral agents, which target viral replication, represent the largest subtype, accounting for approximately 40 % of the treatment portfolio; they are essential in virus‑induced acute cases and include nucleoside analogues and protease inhibitors. Immunomodulatory drugs, comprising about 35 % of the market, modulate host immune responses through cytokine inhibition, T‑cell regulation, or monoclonal antibodies, and are predominantly employed in chronic and relapsing forms. Neuroprotective compounds, a smaller yet growing segment at 15 %, aim to preserve neuronal integrity by mitigating oxidative stress and excitotoxicity, often used as adjuncts across disease stages. Supportive‑care therapies, representing the remaining 10 %, encompass symptomatic management such as analgesics, antipyretics, and rehabilitation services. The relative weight of each type directly influences R&D pipelines, pricing dynamics, and reimbursement policies, as manufacturers allocate resources to the sub‑categories that promise the greatest clinical impact and market return.
